TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma

Glioblastoma (GBM) remains an aggressive brain tumor with a high rate of mortality. Immune checkpoint (IC) molecules are expressed on tumor infiltrating lymphocytes (TILs) and promote T cell exhaustion upon binding to IC ligands expressed by the tumor cells. Interfering with IC pathways with immunot...

Full description

Bibliographic Details
Main Authors: Itay Raphael, Rajeev Kumar, Lauren H. McCarl, Karsen Shoger, Lin Wang, Poorva Sandlesh, Chaim T. Sneiderman, Jordan Allen, Shuyan Zhai, Marissa Lynn Campagna, Alexandra Foster, Tullia C. Bruno, Sameer Agnihotri, Baoli Hu, Brandyn A. Castro, Frank S. Lieberman, Alberto Broniscer, Aaron A. Diaz, Nduka M. Amankulor, Dhivyaa Rajasundaram, Ian F. Pollack, Gary Kohanbash
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
glioblastoma
immunotherapy
PD1
TIGIT
MDSCs
myeloid suppressor cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.637146/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.637146/full

Similar Items